Document is current

Article History

Received: 8 September 2021

Accepted: 31 January 2022

First Online: 10 February 2022

Declarations

:

: The ethics review board of Nagoya University Hospital approved the study protocol (approval number: 2017-0281). All patients provided written informed consent to participate.

: All patients provided written informed consent for publication.

: Takahiro Okumura received research grants from Ono Pharmaceutical, Bayer Pharmaceutical, Daiichi-Sankyo Pharma, and Amgen Astellas BioPharma, as well as honoraria from Ono Pharmaceutical, Otsuka Pharmaceutical, Novartis Pharma, and Medtronic Japan. Toyoaki Murohara received lecture fees from Bayer Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Sanofi-Aventis, and Takeda Pharmaceutical. Toyoaki Murohara received an unrestricted research grant from the Department of Cardiology of Nagoya University Graduate School of Medicine, as well as honoraria from Astellas Pharma, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharma, Pfizer Japan, Sanofi-Aventis, Takeda Pharmaceutical, and Teijin Pharma. All other authors declare that they have no relationships with industry relevant to the contents of this paper.